The prevalence of allergic diseases has significantly increased in industrialized countries. Allergen-specific immunotherapy (AIT) remains as the only curative treatment. The knowledge about the mechanisms underlying healthy immune responses to allergens, the development of allergic reactions and restoration of appropriate immune responses to allergens has significantly improved over the last decades. It is now well-accepted that the generation and maintenance of functional allergen-specific regulatory T (Treg) cells and regulatory B (Breg) cells are essential for healthy immune responses to environmental proteins and successful AIT. Treg cells comprise different subsets of T cells with suppressive capacity, which control the development and maintenance of allergic diseases by various ways of action. Molecular mechanisms of generation of Treg cells, the identification of novel immunological organs, where this might occur in vivo, such as tonsils, and related epigenetic mechanisms are starting to be deciphered. The key role played by the suppressor cytokines interleukin (IL)-10 and transforming growth factor (TGF)-b produced by functional Treg cells during the generation of immune tolerance to allergens is now well established. Treg and Breg cells together have a role in suppression of IgE and induction of IgG4 isotype allergen-specific antibodies particularly mediated by IL-10.
INTRODUCTION
The immune system has evolved to distinguish and mount appropriate immune responses against potentially harmful pathogens and harmless exogenous-and self-antigens. For these vital functions of immune tolerance development, the immune system uses a large number of mechanisms, whose deregulation may lead to development of tumors, rejection of transplanted organs, graft-versus-host disease, autoimmune diseases, asthma and allergies. The prevalence of many of these immune regulation-related diseases have significantly increased over the last decades. 1, 2 In the case of cancer, malignant cells are able to generate tolerant local microenvironments that promote the generation of tumor antigen-specific regulatory T (Treg) cells, thus blocking proper immune responses against uncontrolled proliferating cells. In contrast, in the case of autoimmune or allergic diseases, mechanisms of breaking of tolerance that impairs function of self-antigen or allergen-specific Treg cells occur. Although deregulation events leading to cancer or to autoimmune and allergic diseases are opposite, the molecular mechanisms involved in such processes share many common pathways. 3 The main clinical manifestations of allergic diseases include allergic rhinitis, allergic asthma, food allergy, atopic dermatitis and anaphylaxis. They are characterized by a Th2-type immune response together with the production of specific immunoglobulin (Ig) E antibodies against environmental proteins, called allergens. 1, 4 Although there are many different ways of symptomatic treatment of allergic diseases, currently, allergen-specific immunotherapy (AIT) by the administration of increasing doses of the causative allergen that induces a state of allergen-specific immune tolerance remains as the single longterm curative treatment of allergic diseases. 5 Although many different clinical trials demonstrated the efficacy of AIT, the development of novel strategies with better therapeutic outcomes, enhanced safety and reduced treatment time are still highly demanded. 6 The knowledge about the mechanisms underlying allergic disease has significantly increased over the last decades. [7] [8] [9] Recent findings in the field have contributed to elucidate key molecular and cellular events involved not only in healthy immune response to allergens but also in breaking-tolerance to allergens or restoration of appropriate immune responses to allergens after AIT. [10] [11] [12] [13] [14] [15] [16] [17] In this context, it is now well accepted that the generation and preservation of functional allergen-specific Treg cells are essential for healthy immune responses to allergens and successful AIT. [18] [19] [20] Treg cells comprise different subsets with suppressive capacity able to inhibit the initiation and development of allergic diseases and allergic patients seem to exhibit a specific impairment in the generation of regulatory T cells.
Mouse immune tolerance models have been well studied and the role of Treg cells in allergen tolerance has been demonstrated in adaptive transfer models. 22 Obviously, in humans, immune tolerance studies are more difficult to obtain evidence at the level of mouse models, but none of the human reported studies have shown any similarity to anti-viral or anti-bacterial vaccines. There are three levels of evidence that prove this concept in humans. First, the relationship of clinical non-reactivity (allergen tolerance) to allergens and immune tolerance could be observed in two types of direct tissue analysis. One of them is investigation of skin late phase responses, and the second one is investigation of nasal mucosa biopsies in allergic rhinitis. These data show decrease in Th2 cells and eosinophils in both cases by AIT and a parallel increase in these tissue Treg cells and their related cytokines. 23, 24 Similar data have been shown also in T-cell epitope peptide immunotherapy. 25 In addition, allergen tolerance in beekeepers is also associated with similar mechanisms and decreased skin late phase responses. 10 Second, direct analysis of human peripheral blood cells without any further culture has been obtained for mechanisms of allergen tolerance in healthy beekeepers, who are exposed to high dose of venom allergens and also during AIT. Allergen tetramer-positive CD4 þ antigen-specific T cells have been analyzed or cytokine-secreting cells have been purified in these studies, and the data demonstrate that allergen-specific Treg cells increase in these clinical allergen tolerance models. 10, 26 Third, in both allergen extract and peptide immunotherapy, peripheral T-cell tolerance has been shown with the development of decreased T-cell reactivity to whole allergens and their T-cell epitope peptides at the cell culture level. 25, 27 The essential role played by the inhibitory cytokines interleukin (IL)-10 and transforming growth factor (TGF)-b produced by Treg cells in the immunosuppression of allergic reactions has been studied in detail during the last decades. In addition, a regulatory/ suppressor role for IL-10-secreting B cells has been recently suggested. 13 Dendritic cells (DCs), natural killer cells, epithelial cells, macrophages and glial cells also express suppressor cytokines such as IL-10 and TGF-b. 28 Apparently, multiple cellular and molecular mechanisms have roles on allergen tolerance. The aim of this review is to discuss mechanisms of immune regulation of allergic diseases with special focus on the role played by the immunosuppressive cytokines IL-10 and TGF-b produced by Treg cells in the establishment of tolerance to allergens.
ROLE OF TREG CELLS IN THE INDUCTION OF IMMUNE TOLERANCE TO ALLERGENS
Treg cells comprise a group of different T-cell subsets with suppressive capacity being essential not only to avoid excessive immune responses to pathogens, but also for the induction of immune tolerance. 29 For long time, it has been accepted based on mouse experiments that exposure to high doses of antigens leads mainly to anergy or clonal deletion of antigen-specific T cells, whereas low doses induce preferentially Treg cells. 30, 31 Recent findings in mice demonstrated that exposure to high doses of antigens through the oral route induced allergen-specific Treg cells, thus supporting the main role of Treg cells in the generation of oral tolerance to allergens. 32, 33 Two broad subsets of CD3 þ CD4 þ Treg cells have been described (Figure 1 38 and TCRgd Treg cells, which can have a role in the inhibition of immune responses to tumors, 39 have been described. There are several important tissues in the body, where the generation of tolerance to allergens through the generation of allergen-specific Treg cells and regulatory B cells take place including tonsils, gastrointestinal mucosa, respiratory tract, skin and oral mucosa. [11] [12] [13] 40, 41 The detailed mechanisms underlying immune tolerance in gastrointestinal tissues have not been completely understood yet. Interestingly, it has been recently shown that human tonsils have important roles in immune tolerance, where the generation of functional allergen-specific iTreg cells occurs by mechanisms partially depending on plasmacytoid DCs (pDCs). 11 In that study, tonsil allergen-specific Treg cells were detected using major histocompatibility complex class II tetramer molecules coupled to specific peptides of the allergen, Bet v 1, which showed allergen-specific suppressive effect on T cells. Supporting these data, two other studies demonstrated that extrathymic Treg cells might develop in tonsils. 42, 43 In addition, T-cell cytokine profile of tonsils from allergic patients is characterized by low levels of interferon (IFN)-g, T-bet and IL-10 with increased Th2/Th1 ratio in polyallergic atopic individuals an indicative of the atopic status. 12 For a long time, it has been an open question how allergen tolerance is broken in sensitized individuals. It was recently demonstrated that triggering of Toll-like receptor (TLR)-4 or TLR8 and proinflammatory cytokines, such as IL-1b and IL-6, breaks allergen-specific T-cell tolerance in human tonsils and peripheral blood. 12 Particularly, myeloid DCs are essential in breaking allergen tolerance, whereas pDCs do not change the tolerance status. Considering that relatively large lingual tonsil is not removed by tonsillectomy and remains life-long intact, it is reasonable to conceive that tonsils represent the immunological sites, where immune tolerance induction during successful sublingual immunotherapy may take place, thus representing a potential novel target for future therapeutic interventions.
11,12
Thymic-derived nTreg cells represent less than 5% of the T-cell population in healthy mice and humans. Concerning the generation of nTreg cells, there are two hypotheses. One suggest that nTreg cells emerge from the thymus as a distinct subset of mature T cells with defined functions. 44 Conversely, other studies demonstrated that Treg may arise from naive T cells in the periphery. 34 The relative contribution of the two pathways in vivo in humans is still unclear. Although a number of studies suggest that thymic differentiation accounts for Treg cells that are specific for self-peptides, peripheral differentiation seems to be required for environmental antigen/allergen-specific T cells, for which an undesired immune response results in pathology. 21, 45 nTreg cells constitutively express high levels of CD25, the alpha chain of the IL-2 receptor and cytotoxic T-lymphocyte antigen-4, a molecule acting as a negative regulator of adaptive immune responses after ligation to CD80 and CD86. 46 They also express program death 1, an immunoreceptor tyrosine-based inhibitory motif-containing receptor, 47 the glucocorticoid-induced tumornecrosis factor receptor family-related gene, CD103 (aEb7 integrin) and CD122 (b chain of IL-2 receptor), whose expression correlates with the suppressive activity of Treg cells (Table 1) . 35 Two different functional subsets of nTreg cells in humans have been defined according to the expression of inducible costimulatory molecule. 48 Other proposed markers for Treg cells include certain chemokine receptors, TLRs, glycoprotein-A repetitions predominant, membrane-bound TGF-b, neuropilin-1, lymphocyte activation gene-3, latency-associated peptide and granzymes ( Table 1) . None of these markers are fully Treg cell specific and are also expressed by other effector T-cell populations. 49, 50 Gene arrays identified additional markers, including G-protein coupled receptor 83 (Gpr83), Ecm1 and Helios. [51] [52] [53] The alpha-chain of the IL-7R (CD127) was proposed as a differentiation marker expressed on activated effector T cells, but not on Treg cells.
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FOXP3 AND MOLECULAR MECHANISMS OF TREG CELL GENERATION
The intracellular forkhead-winged transcription factor FOXP3 (forkhead box P3) has been suggested for long time, as the master switch transcription factor for the differentiation of functional nTreg cell development. 21 In mice, FOXP3 is specifically expressed by nTreg cells, 55, 56 whereas in humans, it might be also expressed in a fraction of activated T cells. 49 In any case, human subjects affected by the immune dysregulation polyendocrinopathy enteropathy-X-linked syndrome or the X-linked autoimmune and allergic dysregulation syndrome, characterized by mutations in FOXP3, suffer from typical severe autoimmune and allergic phenotype starting on from infancy, including eczema, food allergy and eosinophilic inflammation. 57, 58 Studies in the scurfy mouse with impaired capacity to generate functional Treg cells because of deletion in the forkhead domain of FOXP3 have demonstrated an intense multiorgan inflammatory response associated with allergic airway inflammation, a striking hyper IgE, eosinophilia, and dysregulated Th1 and Th2 cytokine production. 59 Recently, the generation of Depletion of Regulatory T cells mice, a bacterial artificial chromosome transgenic mouse line that express the diphtheria toxin receptor coupled to enhanced green fluorescence protein under the control of an additional Foxp3 promoter 60 has allowed the direct in vivo analysis and depletion of FOXP3 þ Treg cells, contributing to elucidate essential in vivo functions of Treg cells. 61, 62 It was demonstrated that the expression of FOXP3 was sufficient to convert non-regulatory CD4 þ CD25 À T cells into T cells with regulatory activity and this conversion can be induced by TGF-b. 34 In addition, allergen-specific human Treg cells generated by retroviral transduction of a transcription unit encoding FOXP3 and allergen-specific TCR ab-chains displayed a classical phenotype of Treg cells and suppressive capacity.
63
FOXP3 exerts suppressive activity by inhibiting the expression of IL-2 and IFN-g in nTreg cells after direct interaction with the Runt-related transcription factor1 (RUNX1). 64 In mice, RUNX transcription factors are essential for maintaining high FOXP3 Gpr83: G-protein coupled receptor 83 51, 52 ECM1: extracellular matrix protein 1 51, 52 HELIOS: ikaros transcription factor member 51, 52 GITR: glucocorticoid-induced TNFR gene Abbreviations: DC, dendritic cell; IDO, indoleamine deoxygenase; IL, interleukin; ILT, immunoglobulin-like transcript; MHC, major histocompatibility complex; RA, retinoic acid; RALDH, retinaldehyde dehydrogenase; TGF, transforming growth factor; TNFR, tumor necrosis factor receptor; Treg, regulatory T.
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expression, thus ensuring Treg cell lineage identity. 65 A molecular mechanism linking TGF-b and FOXP3 expression in humans was reported demonstrating that the induction of RUNX1 and RUNX3 by TGF-b is essential for the generation and suppressive function of induced Treg cells. 66 Although TGF-b drives the conversion of naïve T cells into Treg cells, 67 it mainly promotes the generation of Th17 cells in the presence of IL-6. 68 Other metabolites such as retinoic acid contribute to the balance of Th17 and Treg cells by enhancing the expression of FOXP3 through a STAT3/STAT5-independent mechanism. 69 It was also demonstrated that the inhibition of FOXP3 expression by direct GATA3-binding to the promoter region constitutes a mechanism for the inhibition of tolerance by Th2-type immune response. 70 Recent findings indicated that the expression of FOXP3 alone is not sufficient for conferring Treg cell function and phenotype. It was demonstrated that Treg-cell-specific epigenetic changes are also critical for the maintenance of FOXP3 expression, Treg cell differentiation and to establish a stable lineage. 71, 72 In addition, detailed biochemical and mass spectrometry analysis revealed that FOXP3 associates to other transcription factor partners to control distinct aspects of Treg cell biology. 73 Novel findings have also shown that alternative transcriptional programs, including those regulated by FOXO1 control Treg cell function. 74 The study of the epigenetic changes leading to FOXP3 expression and maintenance as well as the role played by other transcriptional programs is a new exciting area of research that may contribute to determine the pathways involved in the establishment of functional nTreg cells.
IL-10-PRODUCING TYPE 1 TREG (TR1) CELLS
In addition to naturally occurring CD4 þ CD25 þ Foxp3 þ Treg cells, Tr1 cells represent a key subset of iTreg cells generated in the periphery after antigenic stimulation characterized by high levels of IL-10 production and regulatory/suppressive properties. 10, 75 Different studies demonstrated that the generation of IL-10-producing Tr1 cells has a very important role in the maintenance of healthy immune response in different diseases, such as allergy, autoimmunity or graft-versus-host disease. 10, 76, 77 Tr1 cells are generated after constant exposure to peripheral antigens in the presence of IL-10. Although the main cytokine produced by Tr1 cells is IL-10, they also produce low/medium levels of TGF-b, IFN-g and IL-5, but not IL-4 nor IL-2, which could be a limitation for therapeutic interventions. 78, 79 Tr1 cells suppress effector T cell responses by mechanisms that depend on IL-10 and also TGF-b and produce perforin and granzymes to kill antigen-presenting cells. 75 A strategy designed to generate Tr1 cell-secreting IL-10, in the absence of Th1-and Th2-associated cytokines, has utilized in vitro stimulation of CD4 þ cells in the presence of glucocorticoids, either alone or more effectively, together with the active form of vitamin D, 1a25-dihydroxyvitamin D3, cytokines (IL-10 and IFN-a or TGF-b and IL-27) or anti-CD3 in combination with anti-CD46 monoclonal antibodies. Similarly, a wide range of antigen administration protocols has been used to induce Tr1 cells, not only in vitro, but also in vivo. These cells were able to regulate autoimmunity in vivo (experimental allergic encephalomyelitis or EAE) in an IL-10-dependent manner. 80 Interestingly, in mice, these drug-induced Tr1 cells were shown to have similar suppressive properties toward naturally occurring Treg cells in vitro. In addition, they were able to inhibit naïve T cells via cell contact-dependent pathways, even though they did not express Foxp3. 81 In humans, these drug-induced Tr1 cells inhibited the proliferation and cytokine responses of naïve as well as established Th1 and Th2 cells, including allergen-specific Th2 cell lines. 82 Interestingly, the enforced expression of IL-10 by transducing human CD4
þ T cells with a bidirectional lentiviral vector encoding for human IL-10 leads to a stable T-cell population that recapitulated the phenotype and function of Tr1 cells. 83 Recent findings demonstrated that the coexpression of CD49b and lymphocyte activation gene--3 identifies human and mouse functional Tr1 cells. 76 The authors proposed the combination of these two markers to track Tr1 cells in vivo and to purify them for cellular therapy aiming at restoration of immune tolerance.
MECHANISMS OF GENERATION OF TREG CELLS: ROLE OF DCS
DCs have an essential role in the initiation of adequate immune responses and directly participate in the generation of functional 
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Treg cells by using different mechanisms. 35 For a long time, the dogma has been that immature or partially mature DCs retain the capacity to generate Treg cells, whereas mature DCs, depending on the stimuli and the specific environments, are able to polarize different effector T-cell subsets. 40 Recent studies demonstrated that fully matured DCs are also able to generate functional Treg cells under certain conditions. 11, 84 The capacity of mature DCs to polarize Treg cell responses is conditioned by specific probiotic or pathogen-derived molecules, by FOXP3 þ Treg cells and by exogenous signals (for example, vitamin D3 metabolites, retinoic acid, adenosine and histamine; [85] [86] [87] Figure 2 ). For example, vitamin D was demonstrated to act on different DC subsets conditioning their capacity to generated Tr1 cells or FOXP3 þ Treg cells. 85 In the same way, retinoic acid, a metabolite derived from vitamin A, favors the maintenance of Treg cells by inhibiting the formation of inflammatory Th17 cells. DCs use a large number of soluble molecules such as cytokines with tolerogenic capacity (for example, TGF-b and IL-10), distinct metabolites (for example, retinoic acid) and specific enzymes (for example, indoleamine 2,3-dioxygenase or retinaldehyde dehydrogenase to polarize Treg cells (Table 1 ). In addition, different costimulatory molecules expressed by DCs, such as ILT-3, ILT-4, CD80, CD86, inducible costimulator-ligand, programmed death-ligand 1 and major histocompatibility complex-II, contribute to the generation and expansion of functional Treg cells (Table 1) . Myeloid DCs and pDCs constitute two complementary and specialized DC subsets exhibiting different functional roles. Myeloid DCs express TLR2-6 and -8 and respond to bacterial and viral infections by producing large amounts of IL-12, whereas pDCs express TLR-7 and -9, and represent the main producers of type I IFNs after viral infections.
84,88
MECHANISMS OF IMMUNE SUPPRESSION BY TREG CELLS
Treg cells use four main mechanisms of suppression that are mediated by many soluble and membrane-bound suppressor factors (Table 1) A and B) . 10, 36, 37, 89 In allergic diseases, Treg cells are able to suppress both the sensitization and effector phases through different modes of action, which include cell contactdependent mechanisms as well as secreted cytokine-dependent ones.
Treg cells directly or indirectly are able to suppress almost all cell types contributing to the ongoing allergic reactions including B cells, DCs, T cells, effector cells (mast cells and basophils), eosinophils as well as specific inflamed tissue cells (Figure 2) . 35 Treg cells act on B cells to promote the production of allergenspecific IgG4, whereas inhibiting IgE 90 and directly inhibiting the activation of allergen-specific Th2, Th1 and Th17 cells, thus blocking all the specific effects mediated by these cells during allergic reactions. Treg cells also induce the generation of tolerogenic DC phenotypes and also inhibit DC maturation. 91 In addition, Treg cells are directly or indirectly able to inhibit allergen-induced activation and degranulation of mast cells and bashophils 92 and impair the infiltration of eosinophils and other effector T cells into inflamed tissues by cytokine-dependent rather than cell-cell contact-dependent mechanisms. 93 Treg cells were are able to suppress mast cell FceRI expression by a mechanism independent of IL-10 and TGF-b as well as mast cell degranulation through OX40-OX40L interactions. 92, 94, 95 Furthermore, Treg cells interact with resident tissue cells and contribute to tissue remodeling. 94, 95 TGF-b produced by Treg cells in the lung of asthmatic patients represents an important factor in healing with important immunomodulatory and fibrogenic activities that might contribute to the repair of asthmatic airways. 96 The role of TGF-b in asthma is complex and many other cells including eosinophils and tissue resident cells also produce TGF-b. The actual contribution of Treg-derived TGF-b to these processes in asthmatic patients needs to be further investigated.
THE ROLE OF IL-10 IN THE IMMUNE REGULATION OF ALLERGIC DISEASES
IL-10 has a potent immunosuppressive capacity that has an essential role not only in the establishment of peripheral tolerance to allergens, but also in protecting the host from exaggerated inflammatory responses to pathogens as well as autoimmune diseases. 85, 97, 98 In humans, IL-10 is mainly produced by Inhibits survival and cytokine production Inhibits mast cell activation, including cytokine production Inhibits chemokine and pro-inflammatory cytokine production Promotes chemotaxis Variable effects on other functions; that is, inhibit expression of FceR Abbreviations: APC, antigen-presenting cell; IL, interleukin; TGF, transforming growth factor; Treg cell, regulatory T cell. 99, 100 IL-10 is secreted as a homodimer consisting of two subunits of 178 amino acids (18 kDa).
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101,102 IL-10 binds to a receptor complex composed of two IL-10R1 chains and two IL-10R2. 103 The IL-10R2 is ubiquitously expressed and the IL-10R1 chain is only expressed on target cells including T cells, B cells, natural killer cells, monocytes, mast cells and DCs. 99, 104 The primary function of IL-10 as an immunosuppressive cytokine is to inhibit the production of proinflammatory cytokines, chemokines and chemokine receptors as well as the expression of class II major histocompatibility complex and costimulatory molecules CD80/CD86 on monocyte/ macrophages and DCs, which in turn leads to indirect inhibition of proliferation of CD4 þ T cells (Table 2) . 105, 106 In addition, IL-10 inhibits T-cell proliferation and cytokine production through direct suppression of T-cell costimulation depending on CD28, inducible costimulatory molecule and CD2. 107, 108 In the context of allergic diseases, the protective role of IL-10 is very well-established. DCs from the respiratory tract of healthy individuals constitutively express high levels of IL-10 and this expression is impaired in patients suffering from rhinitis and allergic asthma. 35, 97 In addition, many different clinical trials demonstrated that the generation of IL-10-producing Tr1 cells correlates with the restoration of healthy immune responses to allergens after allergen SIT. [109] [110] [111] Although healthy and allergic individuals display all different subsets of allergen-specific T cells (Th1, Th2 and Tr1 cells), it is the imbalance between Th2 and Tr1 cells what leads to allergy development or recovery. In healthy individuals, allergen-specific Tr1 cells are the predominant T-cell subset and different studies showed that these cells are able to inhibit allergic responses to different allergenic sources such as birch pollen or related food allergens, house dust mite or bee venom.
19,35 IL-10-secreting Tr1 cells not only suppress Th2 immune responses, but also utilize all of the above-described mechanisms of suppression to overcome and inhibit allergic inflammation. Different models of high-dose exposure to allergens showed that the generation of functional IL-10-producing Tr1 cells correlates with the generation of tolerance to allergens. 10, 112 In this regard, a cross-sectional study demonstrated that exposure to high doses of cat allergen leads to tolerance induction, which is associated with elevated levels of allergen-specific IgG4 levels and generation of IL-10-secreting Tr1 cells without new sensitizations or asthma development. 112 Exposure to high doses of bee venom allergen in professional beekeepers during beekeeping season was also demonstrated as a natural mechanism of immune tolerance induction to allergens in humans. 10 This mechanism involves the clonal differentiation and expansion of IL-10-secreting Tr1 cells from allergen-specific Th1 and Th2 cells. Histamine receptor 2, which is also upregulated on specific Th2 cells, suppresses allergen stimulated T cells and enhances IL-10 production. These processes persist as long as venom exposure and returns to previous levels within 2-3 months after the end of beekeeping season. 10 Interestingly, very recent findings demonstrated that IL10-secreting B regulatory (Br1) cells essentially contribute to these mechanisms. 13 Human IL-10-secreting Br1 cells are able to suppress antigen-specific CD4 þ T-cell proliferation. In addition, the major bee venom allergen phospholipase A-specific B cells from non-allergic beekeepers showed increased expression of IL-10 and IgG4, and the frequency of IL-10-secreting phospholipase A-specific B cells increased in allergic patients receiving AIT. These data provide novel information on IL-10-secreting Br1 cells in allergic inflammation in humans. Supporting these findings, other studies in humans reported that the levels of IL-10-secreting CD5 þ B cells in peripheral blood are higher in healthy individuals compared with milk allergic patients after challenge with casein. 113 In mouse models, helminth-induced Br1 cells inhibit Th2 cells and promote the generation Treg cells, which also contribute to the suppression of Th2-mediated allergic inflammation. It was previously shown that in contrast to the inhibitory effects on many cell types, IL-10 enhances the survival of human B cells, their proliferation, isotype switching and differentiation into antibody-secreting cells. 114 Despite this, serum immunoglobulin levels are normal in il-10 À / À .
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THE ROLE OF TGF-b IN THE IMMUNE REGULATION OF ALLERGIC DISEASES
TGF-b is a pleiotropic cytokine with potent regulatory capacity that has a very important role in suppression of immune responses, especially in induction and maintenance of peripheral tolerance to allergens. Treg cells are a major source of TGF-b and in the particular case of Th3 cells, TGF-b is the main effector molecule involved in the generation of oral tolerance. 116, 117 TGF-b1 is the prototypic member of the complex TGF-b superfamily consisting of more than 35 members. 118, 119 TGF-b1 is synthesized and produced as a homodimer propeptide that is constitutively associated to latency-associated peptide to prevent the binding to its receptors. To be functional, mature TGF-b1 requires the degradation or conformational alteration of latencyassociated peptide, which is mediated by proteases, including plasmin, matrix metalloproteinases, thrombospondin 1 and the integrins avb6 or avb8. 120 There are three types of TGF-b receptors (type I, II and III) with different structural and functional properties that can act as homo-or heterodimers. 121 TGF-b receptors are single pass receptors with serine/threonine kinase activity. Type I and II TGF-b receptors display high affinity for TGF-b1, but not for TGF-b2, whereas type III receptor also binds TGF-b2. The TGF-b superfamily can act on virtually all mammalian cell types expressing different combinations of TGF-b receptors. Ligand-induced activation of TGF-b receptors starts an intracellular signaling cascade leading to the activation and nucleus accumulation of SMAD transcription factors that coordinate the transcriptional initiation of target genes. 121, 122 The activation of SMAD-independent pathways, including mitogen-activated protein kinases and phosphoinositide 3-kinase, and other transcription factors such as RUNX-1 and -3 can be also induced contributing to different types of responses. TGF-b inhibits both Band T-lymphocyte proliferation, Th1 and Th2 responses, their differentiation and survival. [123] [124] [125] Although TGF-b inhibits most Ig isotype switching, it can drive the differentiation of IgA-secreting plasma cells in mouse models. 126 TGF-b promotes immature and inhibitory phenotypes on Langerhans cells, DCs and macrophages. 127, 128 The effect of TGF-b on effector cells of allergy is complex and diverse (Table 2) . For example, TGF-b is able to induce chemotaxis, whereas blocking FceRI expression in mast cells. 28 On the other hand, TGF-b is associated with the conversion of naïve CD4 þ CD25 À T cells into functional Treg cells that contribute to the resolution of immune responses. 34, 129 As discussed above, TGF-b induces the expression of FOXP3 expression in naïve CD4 þ T cells and it is essential for in vivo expansion and immunosuppressive capacity of iTreg cells, which might well have very important implications for immune tolerance as well as for the design of alternative mucosal vaccination strategies.
Considering all these diverse immune regulatory properties of TGF-b, the effects of this cytokine in allergic diseases are complex and there is evidence for both promoting and inhibitory effects. It has been suggested that TGF-b expressed by eosinophils and resident tissue cells may have an important role in airway remodeling in asthmatic patients. 130 Airway epithelial cells produce TGF-b that induces the synthesis of collagen-I 131 and inhibits collagenase production 132 in an autocrine manner, thus contributing to particularly airway remodeling and fibrosis in the pathogenesis of asthma. Supporting these data, experiments using anti-TGF-b antibodies or neutralization of Smad-3 demonstrated significant reduction of airway smooth muscle Treg cells and immune regulation of allergic diseases O Palomares et al proliferation, peribronchial fibrosis and mucus production without influencing airway inflammation. 133, 134 In contrast, TGF-b1-deficient mice die by the age of 3 or 4 weeks under germ-free conditions because of wasting syndrome characterized by excessive activation of autoreactive CD4 þ T cells, indicating the predominant role of TGF-b1 in controlling inflammation. 135, 136 In this context, the overexpression of TGF-b1 in ovalbuminspecific CD4 þ T cells abolished airway hyperresponsiveness and airway inflammation induced by ovalbumin-specific Th2 cells in a murine model of allergic asthma. 137 Involvement of TGF-b in the regulation of allergic airway disease by naturally occurring Treg cells has also been reported. 138, 139 The exact contribution of TGF-b in the regulation of human asthma remains to be established. Initial studies demonstrated that atopic patients suffering from asthma showed higher basal levels of TGF-b1 and that these levels were further increased after allergen provocation, which is in line with the role of TGF-b1 in airway wall remodeling. 140 On the other hand, compelling experimental evidence demonstrated the important role of TGF-b, especially after activation of Treg cells, in the control of airway inflammation and restoration of healthy immune responses to allergens. 120 In summary, TGF-b1 has a dual role in the pathogenesis of allergic diseases. From one side, it might act as a negative feedback mechanism to control airway inflammation and inducing T-cell tolerance (protective effect), whereas at the same time, and because of its important role in healing, it is able to induce airway remodeling and fibrosis (promoting effect). Further research will be needed to clarify the paradoxical effect of TGF-b in the regulation of allergic diseases.
CONCLUSIONS
The generation and preservation of allergen-specific Treg cells are essential to maintain healthy immune responses to allergens as well as for the restoration of normal responses after AIT. Our knowledge in the mechanisms operating during Treg cell generation as well as their mode of suppression to inhibit the development and continuation of allergic diseases has significantly increased over the past years. In particular, compelling experimental evidence demonstrated the key role played by the inhibitory cytokines IL-10 and TGF-b produced by Treg cells for the generation of immune tolerance to allergens. Other cell types such as regulatory B cells or DCs producing high levels of IL-10 seem to have also key roles in the initiation and maintenance of immune tolerance as appropriate healthy immune response to allergens. Still little is known regarding the actual capacity and importance of IL-10-producing Tr1 and Br1 cell types in modulating the allergic response in humans. In addition, further research is also required to better understand the paradoxical capacity of TGF-b to prevent and/or promote the development of allergic diseases. The better understanding of the molecular and cellular events implicated in the pathogenesis of the allergic diseases will significantly help the development of better prevention strategies and therapeutic options.
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